Clive P Page
Overview
Explore the profile of Clive P Page including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
2549
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matera M, Calzetta L, Rinaldi B, de Novellis V, Page C, Barnes P, et al.
Expert Opin Drug Discov
. 2025 Feb;
:1-20.
PMID: 39939153
Introduction: The use of laboratory animals is essential to understand the mechanisms underlying COPD and to discover and evaluate new drugs. However, the complex changes associated with the disease in...
2.
Matera M, Calzetta L, Rinaldi B, Belardo C, Facciolo F, Gallina F, et al.
Pulm Pharmacol Ther
. 2024 Oct;
87:102331.
PMID: 39393521
Asthma management often includes inhaled corticosteroids (ICSs), with additional controllers like long-acting muscarinic antagonists (LAMAs) for severe cases. The primary goal of this study was to investigate the pharmacological interaction...
3.
Cazzola M, Page C, Hanania N, Calzetta L, Matera M, Rogliani P
Drugs
. 2024 Sep;
84(10):1251-1273.
PMID: 39327397
Asthma and cardiovascular disease (CVD) often co-exist. When a patient has both conditions, management requires an approach that addresses the unique challenges of each condition separately, while also considering their...
4.
Matera M, Rogliani P, Page C, Calzetta L, Cazzola M
Expert Opin Drug Discov
. 2024 Aug;
19(10):1159-1172.
PMID: 39138872
Introduction: Gefapixant, a P2X 3 receptor antagonist, shows considerable potential in managing refractory or unexplained chronic cough. Clinical trials have consistently demonstrated its efficacy in significantly reducing cough frequency and...
5.
Parnham M, Norris V, Kricker J, Gudjonsson T, Page C
Adv Pharmacol
. 2023 Jul;
98:83-110.
PMID: 37524493
Macrolide compounds, many of which are derived from natural sources, all share a lactone ring structure, but of varying sizes. Their biological activities differ with structure and size but tend...
6.
Cazzola M, Page C, Wedzicha J, Celli B, Anzueto A, Matera M
Respir Res
. 2023 Jul;
24(1):194.
PMID: 37517999
Background: Oxidative stress and persistent airway inflammation are thought to be important contributors to the development of chronic obstructive pulmonary disease (COPD). This review summarizes the evidence for targeting oxidative...
7.
Cazzola M, Page C, Matera M, Rogliani P, Hanania N
Eur Respir J
. 2023 Jul;
62(2).
PMID: 37474159
Several current guidelines/strategies outline a treatment approach to asthma, which primarily consider the goals of improving lung function and quality of life and reducing symptoms and exacerbations. They suggest a...
8.
Cazzola M, Hanania N, Page C, Matera M
Int J Chron Obstruct Pulmon Dis
. 2023 Jul;
18:1333-1352.
PMID: 37408603
Airway inflammation, driven by different types of inflammatory cells and mediators, plays a fundamental role in COPD and its progression. Neutrophils, eosinophils, macrophages, and CD4 and CD8 T lymphocytes are...
9.
Arkless K, Fish M, Jennings A, Page C, Shankar-Hari M, Pitchford S
Shock
. 2023 Jul;
60(2):172-180.
PMID: 37405876
Key underlying pathological mechanisms contributing to sepsis are hemostatic dysfunction and overwhelming inflammation. Platelet aggregation is required for hemostasis, and platelets are also separately involved in inflammatory responses that require...
10.
Stolz D, Matera M, Rogliani P, van den Berge M, Papakonstantinou E, Gosens R, et al.
Breathe (Sheff)
. 2023 Jun;
19(2):220267.
PMID: 37377851
Pharmacological management of airway obstructive diseases is a fast-evolving field. Several advances in unravelling disease mechanisms as well as intracellular and molecular pathways of drug action have been accomplished. While...